Veradigm stock gains 3.04 percent as relisting plans emerge

Veradigm stock (ISIN US01988P1084) gained 3.04 percent to USD 4.90 on September 23, 2026, while the healthcare information company outlined a path back to a national exchange. The price remained 18.33 percent below its 52-week high of USD 6.00, leaving the filing timetable central to the investment case.

Revenue estimate sets a benchmark

According to StockTitan, Veradigm reported on September 15, 2026, that preliminary unaudited 2025 revenue was estimated at USD 584 million to USD 589 million. The presentation also said the 2025 audit was underway and that the company expected to file its 2025 Form 10-K later in 2026.

The revenue range gives investors a concrete scale for the business after a prolonged filing backlog. It also creates a measurable checkpoint: the midpoint of the estimate is USD 586.5 million, while the preliminary range spans USD 5 million from low to high.

Relisting remains tied to filings

The same September 15 filing said Veradigm expects to seek relisting on a national securities exchange once it is current with SEC filings. The company had recently filed its 2023 and 2024 Form 10-K reports, with the 2025 audit still underway.

That sequence links market access to execution rather than to a new operating forecast. Veradigm's common stock is identified as MDRX and the filing lists the venue as OTC Expert Market, a materially different status from a national exchange listing.

Stock stays below yearly high

Veradigm stock stood at USD 4.90 on September 23, 2026, with a daily gain of 1.03 percent. Its 52-week range was USD 3.00 to USD 6.00, so the latest price was USD 1.10 below the yearly high.

More news and analyses on Veradigm stock